For refractory patients with idiopathic thrombocytopenia purpura (ITP), a disorder characterized by immune-mediated platelet destruction, treatment with Rituxan rituximab represents a new option that generated significant interest at the American Society of Hematology meeting in...

The companies restructured their 1999 distribution deal to make Fresenius and its Fresenius HemoCare Inc. subsidiary (Redmond, Wash.) exclusive global distributors of CYPB's Prosorba column treatment for rheumatoid arthritis. Formerly, the distributors held exclusive rights...

CYPB partner Fresenius HemoCare launched in Europe CYPB's Prosorba protein A matrix plasmapheresis column to treat rheumatoid arthritis (RA). Fresenius HemoCare will market the column for use with its Fresenius Cell Separator and Leukocyte Filter...

CYPB and partner Fresenius HemoCare (Bad Homburg, Germany) launched in Europe CYPB's Prosorba protein A matrix plasmapheresis column to treat rheumatoid arthritis. The treatment system includes the Fresenius Cell Separator and Leukocyte Filter....

Canada granted marketing approval for Prosorba to treat rheumatoid arthritis. Medexus Inc. (Toronto, Ontario) will market the product in Canada. Separately, CYPB said that partner Fresenius HemoCare GmbH (Bad Homburg, Germany) received CE Mark approval...

CYPB said partner Fresenius HemoCare (Bad Homburg, Germany) received the CE Mark for CYPB's Prosorba protein A matrix plasmapheresis column to treat rheumatoid arthritis. The product will be launched in the second quarter....

Medexus will exclusively distribute CYPB's Prosorba column in Canada and will pay CYPB the lesser of the pre-determined percentage of Prosorba's net sales or a transfer price. Medexus also will conduct a trial in Canada...

CYPB published in Arthritis and Rheumatism previously reported data from its 109-patient Phase III study in which 31.9 percent of Prosorba-treated patients showed improvement in American College of Rheumatology (ACR) criteria compared to 11.4 percent...

CYPB published in The Journal of Rheumatology data from a pilot study of the column in 15 patients with RA refractory to disease-modifying anti-rheumatic drugs (DMARDs). Patients in the study received Prosorba treatments once a...

Cypress Bioscience Inc. (CYPB), San Diego, Calif. Business: Autoimmune/Inflammation First Security Van Kasper analyst Alan Auerbach began coverage with a "strong buy" and a $6 price target. He said that increased awareness of CYPB's approved...